A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro. After months of high demand and supply constraints, this news marks a significant ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Shares plummeted by almost eight percent on Wednesday, with Zepbound and diabetes drug Mounjaro — the active ingredient in both is tirzepatide, a GLP-1 receptor agonist — missing Wall Street ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like Peptide (GLP-1) products, such as Ozempic, on the local ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs ... Last month, the FDA said ...

A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy ... FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also used ...